Literature DB >> 1648925

Herpes and human ribonucleotide reductases. Inhibition by 2-acetylpyridine 5-[(2-chloroanilino)-thiocarbonyl]-thiocarbonohydrazone (348U87).

T Spector1, J A Harrington, D J Porter.   

Abstract

The mode of inactivation of herpes simplex virus type 1 and human ribonucleotide reductases by 2-acetylpyridine 5-[(2-chloroanilino)-thiocarbonyl]-thiocarbonohydrazone++ + (348U87) was determined and compared to that described previously [Porter et al. Biochem Pharmacol 39: 639-646, 1990] for 2-acetylpyridine 5-[(dimethylamino)thiocarbonyl]-thiocarbonohydrazone (A1110U). 348U87 inactivated herpes ribonucleotide reductase faster than did A1110U. Moreover, iron-complexed 348U87 was a considerably more potent inactivator than iron-complexed A1110U. It appeared to efficiently form an initial complex with the viral enzyme prior to rapid enzyme inactivation. The combination of 348U87 and iron-complexed 348U87 inactivated with a rate constant that was slightly greater than the sum of their individual rate constants of inactivation. The corresponding combination of A1110U species inactivated with a rate constant that was much greater than the sum of the individual rate constants of inactivation. Herpes ribonucleotide reductase that had been inactivated by either species of 348U87 was reactivated by diluting the enzyme and inactivators into assay medium containing excess iron. 348U87 was also an effective inactivator of herpes simplex virus type 2 and varicella zoster virus ribonucleotide reductases. The iron-complexed forms of 348U87 and A1110U exhibited very different modes of inactivation of human ribonucleotide reductase. Iron-complexed 348U87 was a tight-binding inactivator, whereas iron-complexed A1110U was only a weak, non-inactivating, inhibitor. Furthermore, the inactivation by iron-complexed 348U87 was not stimulated by either 348U87 or A1110U, whereas the weak inhibition by iron-complexed A1110U was converted to rapid inactivation by A1110U. Excess iron prevented the inactivation by iron-complexed 348U87. Uncomplexed 348U87 was similar to uncomplexed A1110U in that it was not an inhibitor of the human enzyme.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1648925     DOI: 10.1016/0006-2952(91)90685-x

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  8 in total

1.  Strategic design and three-dimensional analysis of antiviral drug combinations.

Authors:  M N Prichard; L E Prichard; C Shipman
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

2.  Topical treatment of infection with acyclovir-resistant mucocutaneous herpes simplex virus with the ribonucleotide reductase inhibitor 348U87 in combination with acyclovir.

Authors:  S Safrin; T Schacker; J Delehanty; E Hill; L Corey
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

3.  Inactivators of herpes simplex virus ribonucleotide reductase: hematological profiles and in vivo potentiation of the antiviral activity of acyclovir.

Authors:  T Spector; D C Lobe; M N Ellis; T A Blumenkopf; G M Szczech
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

4.  2-Acetylpyridine 5-[(dimethylamino)thiocarbonyl]-thiocarbonohydrazone (1110U81) potently inhibits human cytomegalovirus replication and potentiates the antiviral effects of ganciclovir.

Authors:  F M Hamzeh; T Spector; P S Lietman
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

5.  Antiviral activity of a selective ribonucleotide reductase inhibitor against acyclovir-resistant herpes simplex virus type 1 in vivo.

Authors:  J Duan; M Liuzzi; W Paris; M Lambert; C Lawetz; N Moss; J Jaramillo; J Gauthier; R Déziel; M G Cordingley
Journal:  Antimicrob Agents Chemother       Date:  1998-07       Impact factor: 5.191

Review 6.  Current pharmacological approaches to the therapy of varicella zoster virus infections: a guide to treatment.

Authors:  R Snoeck; G Andrei; E De Clercq
Journal:  Drugs       Date:  1999-02       Impact factor: 11.431

7.  Inhibition of herpes simplex virus type 1 and adenovirus type 5 by heterocyclic Schiff bases of aminohydroxyguanidine tosylate.

Authors:  A Das; M D Trousdale; S Ren; E J Lien
Journal:  Antiviral Res       Date:  1999-12-31       Impact factor: 5.970

8.  High-Throughput Screening of the ReFRAME Library Identifies Potential Drug Repurposing Candidates for Trypanosoma cruzi.

Authors:  Jean A Bernatchez; Emily Chen; Mitchell V Hull; Case W McNamara; James H McKerrow; Jair L Siqueira-Neto
Journal:  Microorganisms       Date:  2020-03-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.